Another phase I trial studying the combination of talazoparib and irinotecan with and without TMZ in pediatric patients with recurrent or refractory solid tumors included a single patient with NB who had SD [78], again suggesting there may be a benefit of targeting PARP as part of a drug combination in a subset of patients with NB. This evidence concerns the gene PARP1 and neuroblastoma.